Long non-coding RNAs in schizophrenia

Abstract

Long noncoding RNAs (lncRNAs) have emerged as critical regulators of the pathogenesis of schizophrenia, a complex neuropsychiatric disorder influenced by genetic and environmental factors. These transcripts modulate gene expression through diverse mechanisms, including chromatin remodeling, transcriptional regulation, and posttranscriptional modifications. Recent studies have demonstrated significant alterations in lncRNA expression profiles in both the peripheral blood and brain tissues of schizophrenia patients, highlighting their potential as biomarkers and therapeutic targets. Dysregulated lncRNAs such as Gomafu, DISC-2, BDNF-AS, MEG3, and TUG1 have been linked to neurodevelopmental processes, inflammatory responses, and key synaptic plasticity pathways implicated in schizophrenia. Furthermore, antipsychotic treatments have been shown to influence lncRNA expression, which is correlated with symptom improvement. Sex-specific and age-related differences in lncRNA regulation further underscore their complexity and relevance to schizophrenia pathophysiology. This review consolidates current knowledge on the role of lncRNAs in schizophrenia, emphasizing their diagnostic potential.